

**AMENDMENT TO RULES COMM. PRINT 117-31**

**OFFERED BY MR. JACKSON OF TEXAS**

Page 844, after line 15, add the following:

1           (28) Decades of policies rooted in socialism  
2           have stifled United States domestic pharmaceutical  
3           drug manufacturing and left the United States ex-  
4           posed to the hostile actions and unfair trade prac-  
5           tices of the People’s Republic of China.

6           (29) Until the recent enactment of the Tax  
7           Cuts and Jobs Act, the United States had one of the  
8           least competitive tax systems in the world, causing  
9           decades of manufacturing job losses and increased  
10          offshoring of vital industries.

11          (30) The novel coronavirus (COVID-19) out-  
12          break compounded national security and public  
13          health concerns and highlighted vulnerabilities re-  
14          garding the American health care system’s reliance  
15          on foreign nations, particularly China, for medical  
16          supplies and pharmaceuticals.

17          (31) The Communist Chinese regime has  
18          sought to take advantage of these burdens and use  
19          its own tariffs, subsidies, and anticompetitive poli-

1       cies to gain a comparative advantage in the manu-  
2       facturing of active pharmaceutical ingredients.

3           (32) China is leveraging military modernization  
4       and predatory economics to reorder the Indo-Pacific  
5       region to its advantage and to displace the United  
6       States in its efforts for global dominance.

7           (33) In October 2019, the Food and Drug Ad-  
8       ministration testified that China has increased pro-  
9       duction of active pharmaceutical ingredients over the  
10      past decade, driven by industry desire for cost-sav-  
11      ings and less stringent regulatory structures.

12          (34) In that testimony, the Food and Drug Ad-  
13      ministration noted that current data capabilities  
14      leave gaps in understanding the exact volume of for-  
15      eign-sourced active pharmaceutical ingredients being  
16      used for domestic drugs, the volume being produced  
17      at Chinese facilities, and where Chinese active phar-  
18      maceutical ingredients are being distributed world-  
19      wide.

20          (35) China intends to continue using United  
21      States self-imposed economic constraints to push the  
22      United States out of global affairs and to dismantle  
23      the free market structures that have lead to unprec-  
24      edented global prosperity.

1           (36) The threat imposed by China is dependent  
2           on the United States continuing decades of domestic  
3           policies that have stifled development and crippled  
4           the United States manufacturing base.

5           (37) The people and industries of the United  
6           States possess the skillsets, tools, and innovative  
7           spirit to restore the United States pharmaceutical  
8           manufacturing base and to fully counter the unfair  
9           and anticompetitive practices of the Communist Chi-  
10          nese regime.

Page 857, after line 3, add the following:

11          (9) Committing to the competitive free market  
12          and free trade policies that allowed the United  
13          States to become the wealthiest and most advanced  
14          nation on Earth.

15          (10) Committing to combating, through the use  
16          of free market policies, the present national security  
17          threat caused by the Communist Chinese regime and  
18          its attacks on the United States pharmaceutical  
19          manufacturing base.

20          (11) Removing the Federal tax, regulatory, and  
21          debt burdens and barriers that have weakened the  
22          United States pharmaceutical manufacturing base.

23          (12) Empowering the United States Trade Rep-  
24          resentative to call on the international community,

1 to adopt competitive free trade and free market poli-  
2 cies, and to counter the harmful and unfair trade  
3 practices of the Communist Chinese regime.

4 (13) Addressing shortcomings in Food and  
5 Drug Administration data collection to better under-  
6 stand the exact nature of United States reliance on  
7 foreign-sourced advanced pharmaceutical ingredi-  
8 ents.

9 (14) Identifying and streamlining Food and  
10 Drug Administration regulatory hurdles that have  
11 stifled the United States pharmaceutical manufac-  
12 turing base and that have promoted foreign supply  
13 lines and offshoring United States industry.

